Data Insights

AZD-9574 by AstraZeneca for Cervical Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Cervical Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Cervical Cancer

Data Insights

AZD-9574 by AstraZeneca for Endometrial Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Endometrial Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Endometrial Cancer

Data Insights

AZD-9574 by AstraZeneca for Vaginal Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Vaginal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Vaginal Cancer

Data Insights

AZD-9574 by AstraZeneca for Vulvar Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Vulvar Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Vulvar Cancer

Data Insights

Risk adjusted net present value: What is the current valuation of AstraZeneca's AZD-9574?

AZD-9574 is a small molecule commercialized by AstraZeneca, with a leading Phase II program in Vaginal Cancer. According to Globaldata,...

Net Present Value Model: AstraZeneca Plc's AZD-9574

Data Insights

AZD-9574 by AstraZeneca for Colorectal Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Colorectal Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Colorectal Cancer

Data Insights

AZD-9574 by AstraZeneca for Gastric Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Gastric Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Gastric Cancer

Data Insights

AZD-9574 by AstraZeneca for Bladder Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Bladder Cancer. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Bladder Cancer

Data Insights

AZD-9574 by AstraZeneca for Non-Small Cell Lung Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Non-Small Cell Lung Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Non-Small Cell Lung Cancer

Data Insights

AZD-9574 by AstraZeneca for Metastatic Biliary Tract Cancer: Likelihood of Approval

AZD-9574 is under clinical development by AstraZeneca and currently in Phase II for Metastatic Biliary Tract Cancer. According to GlobalData,...

Likelihood of Approval and Phase Transition Success Rate Model - AZD-9574 in Metastatic Biliary Tract Cancer